Bradykinin (2-9)

SKU: orb1219864

Description

Bradykinin (2-9) is a metabolite of Bradykinin, cleaved by Aminopeptidase P. Bradykinin (2-9) is an amino-truncated Bradykinin peptide. The Bradykinin peptide system is a tissue-based system with potent cardiovascular and renal effects. To investigate the regulation of this system, a highly sensitive amino terminal-directed radioimmunoassay that, with high performance liquid chromatography, enables the measurement of Bradykinin-(1-7), Bradykinin-(1-8), and Bradykinin-(1-9), is developed. Together with a carboxy terminal-directed radioimmunoassay, Bradykinin peptides in rat kidney and blood are characterized. The predominant Bradykinin peptides in kidney are Bradykinin-(1-9) (~100 fmol/g wet weight of tissue) and Bradykinin-(1-7) (~70 fmol/g), with low levels of Bradykinin-(1-8) (~8 fmol/g) and Bradykinin-(4-9) (~12 fmol/g) detectable; Bradykinin-(2-9) and Bradykinin-(3-9) are below the limits of detection. In blood, the levels of Bradykinin-(1-9) are very low (~2 fmol/ml), and other Bradykinin peptides are below the limits ofdetection. Administration of the angiotensin converting enzyme (ACE) inhibitor Perindopril is associated with an approximate twofold increase in renal levels of Bradykinin-(1-8) and Bradykinin-(1-9) and a decrease in the Bradykinin-(1-7)/Bradykinin-(1-9) ratio. The amino terminal-directed radioimmunoassay is also applied to heart, aorta, brown adipose tissue, adrenal, lung, and brain. For these tissues, Bradykinin-(1-7) and Bradykinin-(1-9) are of similar abundance (16-340 fmol/g), with lower levels of Bradykinin-(1-8).

Key Properties

• CAS Number: 16875-11-9
• MW: 904.02
• Purity: >98% (HPLC)
• Formula: C₄₄H₆₁N₁₁O₁₀
• SMILES: NC(=N)NCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1)C(O)=O
• Target: Bradykinin Receptor
• Solubility: In Vitro: DMSO : 100 mg/mL (110.62 mM)

Bioactivity

• In Vitro:
  The Bradykinin peptide system is a tissue-based system with potent cardiovascular and renal effects. To investigate the regulation of this system, a highly sensitive amino terminal-directed radioimmunoassay that, with high performance liquid chromatography, enables the measurement of Bradykinin-(1-7), Bradykinin-(1-8), and Bradykinin-(1-9), is developed. Together with a carboxy terminal-directed radioimmunoassay, Bradykinin peptides in rat kidney and blood are characterized. The predominant Bradykinin peptides in kidney are Bradykinin-(1-9) (~100 fmol/g wet weight of tissue) and Bradykinin-(1-7) (~70 fmol/g), with low levels of Bradykinin-(1-8) (~8 fmol/g) and Bradykinin-(4-9) (~12 fmol/g) detectable; Bradykinin-(2-9) and Bradykinin-(3-9) are below the limits of detection. In blood, the levels of Bradykinin-(1-9) are very low (~2 fmol/ml), and other Bradykinin peptides are below the limits ofdetection. Administration of the angiotensin converting enzyme (ACE) inhibitor Perindopril is associated with an approximate twofold increase in renal levels of Bradykinin-(1-8) and Bradykinin-(1-9) and a decrease in the Bradykinin-(1-7)/Bradykinin-(1-9) ratio. The amino terminal-directed radioimmunoassay is also applied to heart, aorta, brown adipose tissue, adrenal, lung, and brain. For these tissues, Bradykinin-(1-7) and Bradykinin-(1-9) are of similar abundance (16-340 fmol/g), with lower levels of Bradykinin-(1-8).

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Des-Arg1-bradykinin

Quick Database Links

Gene Symbol

Bradykinin Receptor